1 Original article

2

3	Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus
4	dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast
5	cancer: A prospective pilot study
6	
7	Authors: Yu Zhang ^{1,2,3,4†} , Shuo Cao ^{1†} , Nan Niu ^{1,2,3†} , Huilian Shan ^{1†} , Jinqi Xue ^{1,2,3†} ,
8	Guanglei Chen ^{1,2,3} , Yongqing Xu ¹ , Jianqiao Yin ¹ , Chao Liu ^{1,2,3} , Lisha Sun ^{1,2,3} , Xiaofan
9	Jiang ^{1,2,3} , Meiyue Tang ¹ , Qianshi Xu ^{1,2} , Mingxuan Jia ¹ , Xu Zhang ¹ , Zhenyong Zhang ¹ ,
10	Qingfu Zhang ⁵ , Jianfei Wang ⁶ , Ailin Li ¹ , Yongliang Yang ^{7*} , Caigang Liu ^{1,2,3*}
11	
12	Author Affiliations:
13	¹ Department of Oncology, Shengjing Hospital of China Medical University,
14	Shenyang, China;
15	² Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of
16	China Medical University, Shenyang, China;
17	³ Innovative Cancer Drug Research and Development Engineering Center of Liaoning
18	Province, Shenyang, China.;
19	⁴ Department of Gastrointestinal Surgery, Yantai Affiliated Hospital of Binzhou
20	Medical University, Yantai, China;
21	⁵ Department of Pathology, the First Affiliated Hospital and College of Basic Medical
22	Sciences of China Medical University, Shenyang, China;
23	⁶ Jiangsu Hengrui Pharmaceuticals, Shanghai, China;

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

⁷ School of Bioengineering, Dalian University of Technology, Dalian, China.

25 Authors' contributions

26	S. Cao, Data curation, formal analysis, methodology, writing-original draft. G. Chen,
27	Data curation, methodology. J. Xue, Data curation, methodology. N. Niu, Validation,
28	data curation, formal analysis, methodology, writing-review and editing. Y. Zhang:
29	Data curation, formal analysis, methodology. Y. Xu, Methodology. J. Yin,
30	Methodology. C. Liu, Formal analysis, methodology. L. Sun, Methodology. X. Jiang,
31	Writing-original draft. M. Tang, Data curation. Q. Xu, Formal analysis. M. Jia,
32	Methodology. X. Zhang, Methodology. Z. Zhang, Methodology. Q. Zhang, Formal
33	analysis. H. Li, Formal analysis. A. Li, Conceptualization, methodology. Y. Yang,
34	Methodology, writing-review and editing. Caigang Liu, Conceptualization,
35	supervision, project administration, writing-review and editing.
36	Shuo Cao, Yu Zhang, Jinqi Xue and Guanglei Chen contributed equally to this work.
37	
38	Corresponding author:
39	Caigang Liu, MD, PhD
40	Department of Oncology, Shengjing Hospital of China Medical University, Shenyang 110004,
41	China
42	Tel.: 86-18940254967
43	E-mail: liucg@sj-hospital.org
44	

46

- 47
- 48
- 49 Abstract

Background: Both neoadiuvant chemotherapy and endocrine therapy only result in 50 51 trivial pathological complete response rates and moderate objective response rates 52 (ORR) in hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative breast cancer, more promising alternatives are urgently needed. 53 With proven synergistic effect of cyclin dependent kinase 4/6 (CDK4/6) inhibitor and 54 55 radiotherapy in preclinical studies, this pilot study aimed to explore the efficacy and safety of neoadjuvant stereotactic body radiation therapy (SBRT) followed by 56 dalpiciclib and exemestane in HR-positive, HER2-negative breast cancer. 57

58 **Methods:** This was a single-arm, non-controlled prospective pilot study. Treatment-59 naïve patients with unilateral HR-positive, HER2-negative breast cancer received 60 neoadjuvant radiotherapy (24Gy/3F) followed by dalpiciclib and exemestane for 6 61 cycles. The primary endpoint was the proportion of patients with residual cancer 62 burden (RCB) score of 0-I. Key secondary endpoints included ORR, biomarker 63 analysis, and safety.

Results: All 12 enrolled patients completed the study treatment and surgery. Two
(16.7%) of them achieved the RCB 0-I with the ORR of 91.7% (11/12). Analyses of
tumor specimens showed significant increase of infiltrating T cells rather than

67	alteration of PD-L1 positive immune cells. The most common grade 3 adverse events
68	(AEs) were neutropenia (66.7%) and leukopenia (25.0%), but no grade 4-5 AE or
69	death occurred.
70	Conclusions: Our results suggested neoadjuvant SBRT followed by dalpiciclib and
71	exemestane are effective and tolerable, and provides novel insights for the
72	neoadjuvant treatment of HR+/HER2- breast cancer, which may be considered as an
73	alternative to patients with HR-positive, HER2-negative breast cancer.
74	
75	
76	Funding: None
77	
78	Clinical trial number: NCT05132790
79	
80	Impact statement: Neoadjuvant SBRT with dalpiciclib and exemestane resulted
81	in a 16.7% RCB 0-I rate and a 91.7% ORR, with acceptable toxicities in HR-
82	positive, HER2-negative breast cancer patients.

83 Introduction

Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-84 85 negative breast cancer is the most prevalent subtype of breast cancer, which accounts for approximately 70% of all breast cancer (Parker et al., 2009). Neoadjuvant 86 87 chemotherapy (NCT) is recommended as the first-choice for patients with HRpositive, HER2-negative breast cancer, who are candidates for preoperative therapy, 88 according to National Comprehensive Cancer Network (NCCN) guidelines(Gradishar 89 90 et al., 2022). Neoadjuvant endocrine therapy (NET) is an acceptable, less toxic 91 alternative of NCT. However, less than 10% of patients with HR-positive, HER2negative breast cancer can achieve pathological complete response (pCR), and only 92 93 60% of patients respond to NCT or NET (Sella et al., 2021). Hence, more promising 94 alternatives are urgently needed.

Cyclin dependent kinase 4/6 (CDK4/6) inhibitors are breakthroughs in the treatment 95 of HR-positive, HER2-negative breast cancer, and have a remarkable efficacy in the 96 97 advanced setting when combined with endocrine therapy (ET) (Finn et al., 2015; Goetz et al., 2017; Hortobagyi et al., 2016) . Presently, abemaciclib has been 98 99 approved for high-risk, early HR-positive breast cancer plus ET as adjuvant treatment 100 and its application is being explored in neoadjuvant setting (neoMONARCH and 101 NCT04293393). However, therapies with combination of CDK4/6 inhibitors and NET only achieve a pCR rate of less than 5% (Hurvitz et al., 2020; Johnston et al., 102 103 2019) .In the PALLET study, objective response rate (ORR) was not statistically

significantly different between the combinational therapy and monotherapy (54.3% vs
49.5%, P = 0.20) (Johnston et al., 2019). Likewise, in the FELINE study, there was
no statistical difference in clinical, mammographic, ultrasound or magnetic resonance
imaging (MRI) response between letrozole alone and combination of letrozole with a
CDK4/6 inhibitor(Khan et al., 2020). Thus, it is reasonable to explore a novel
neoadjuvant therapy for HR-positive, HER2-negative breast cancer.

Radiotherapy is one of the most important local methods to control malignancy by 110 breaking DNA in tumor cells (Cox & Swanson, 2013). Stereotactic body radiation 111 112 therapy (SBRT) is a novel and relatively safe radiotherapy technique and delivers high doses of radiation in a small number of fractions to the tumor lesion while 113 minimizing radiation exposure to the surrounding tissues(Chmura et al., 2021). 114 115 Currently, neoadjuvant radiotherapy can be applicable for inoperable breast cancer to allow an effective and sometimes more conservative surgery (Cardoso et al., 2018). 116 Preclinical studies have indicated that CDK4/6 inhibitors can sensitize breast cancer 117 118 cells to radiotherapy, possibly by inhibition of DNA damage repair response, enhancement of apoptosis and blockage of cell cycle progression, and inhibition of 119 intra-tumor cellular metabolism and angiogenesis (Han et al., 2013; A. M. Pesch et al., 120 2020; G. Petroni et al., 2021). A preclinical study has explored different schedules of 121 combination of radiotherapy and CDK4/6 inhibitors in human and mouse model and 122 demonstrated that radiotherapy followed by CDK4/6 inhibitors can enhance 123 124 antineoplastic effects, compared with their monotherapy alone or CDK4/6 inhibitors

concurrent with or followed by radiotherapy (G. Petroni et al., 2021). Moreover, the
combination of CDK4/6 inhibitors and radiotherapy can lead to a satisfying overall
disease control and safety based on several retrospective studies in metastatic breast
cancer (Bosacki et al., 2021). Nevertheless, the efficacy and safety of this regimen in
neoadjuvant treatment of early-stage HR-positive, HER2-negative breast cancer are
unknown.
We have conducted a prospective pilot study to determine the efficacy and safety of

neoadjuvant radiotherapy followed by dalpiciclib and exemestane in patients with
newly-diagnosed early or locally advanced HR-positive, HER2-negative breast cancer.
Dalpiciclib (SHR6390) is a potent selective inhibitor of CDK4/6 and exerts
synergistic anti-tumor effect when combined with endocrine therapy for advanced
luminal breast cancer in the DAWNA-1 trials (Xu et al., 2021).

137

138 Methods

139 Study design

This single-arm, non-controlled prospective pilot study in women with HR-positive,
HER2-negative early or locally advanced breast cancer was registered with
ClinicalTrials.gov (NCT05132790).

The study was approved by the Institutional Review Board and Ethics Committee of
Shengjing Hospital of China Medical University, according to the Declaration of
Helsinki and Good Clinical Practice guidelines. Written informed consent was

146 obtained from each patient.

147

148 Participants

Eligible patients included pre- and post-menopausal women aged between 18 and 75 149 150 years, with histologically confirmed HR-positive, HER2-negative (0 or 1+ by 151 immunohistochemistry [IHC], or 2+ by IHC with negative results of fluorescence in situ hybridization) invasive breast cancer at stage II-III with the lesion of ≥ 2 cm by 152 153 MRI. Other main inclusion criteria were Eastern Cooperative Oncology Group 154 performance status 0-1, adequate marrow, hepatic and renal function. The key exclusion criteria included stage IV tumors, inflammatory breast cancer, prior 155 156 systemic treatment of the current cancer, other malignancies, cardiac disease or 157 history of cardiac dysfunction, pregnancy, lactation, and refusal to use contraception.

158

159 **Procedures**

SBRT was performed every other day in breast target lesion with a total radiation dose of 24Gy separated by 3 fractions. Within 2-4 weeks after the completion of radiotherapy, individual patients received 6 cycles of combination of oral 150 mg Dalpiciclib daily on days 1-21 of each 4-week cycle and 25 mg exemestane with a total duration of 24 weeks. Patients without menopause were also injected subcutaneously with 3.6 mg goserelin every 4 weeks. All patients received study treatment until completion of all prescribed protocol therapy, disease progression,

unacceptable toxicity, or withdrawal of consent. If disease progression, the patient
was either proceed to surgery or received alternative neoadjuvant therapy. Surgery
was performed 3-5 weeks after the last dose of dalpiciclib to allow adverse event (AE)
recovery. Recommended surgery and adjuvant therapy followed per local guidelines
or institutional standards. The necessity of additional chemotherapy for patients with
pCR was judged by investigators.

173

174 Outcomes

175 The primary endpoint was the rate of residual cancer burden (RCB) 0-I. Secondary endpoints included ORR (defined as the proportion of patients with complete or 176 177 partial response according to the Response Evaluation Criteria In Solid Tumors 178 [RECIST] version 1.1 by MRI), pCR rate in the breast and axillary lymph nodes (tpCR; ypT0/is ypN0) and in the breast (bpCR; ypT0/is ypNx), preoperative 179 endocrine prognostic index (PEPI) score for breast cancer-specific survival (BCSS) 180 181 (PEPI 0), and safety, according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. 182

183

184 Patient-Reported Outcome (PRO) assessments

In the study, the patient-reported outcome (PRO) assessments was measured using the
European Organization for Research and Treatment of Cancer (EORTC) Quality of
Life Questionnaire Core-30 (QLQ-C30; version 3) (Cull, 1998) at baseline, at the end

188 of cycles 1 to 6, and before surgery. The PRO data were scored, according to the 189 EORTC scoring manual. A raw score was calculated as the average of items 190 contributing to a scale and standardized to a range of 0 to 100 points. On global health 191 status and functioning scales, a higher score indicated better status. Higher scores on 192 symptom scales indicated worse symptoms.

193

194 Tumor-infiltrating lymphocytes (TILs)

Tumor samples were collected when performing needle biopsy and surgery. The 195 196 specimens were fixed in 10% formalin and paraffin-embedded. The tissue sections (3 µm) were stained with hematoxylin and eosin (H&E) and the frequency of TILs were 197 quantified manually by a pathologist in a blinded manner. The TILs scores were 198 199 determined as the percentage of TILs in tumor area (tumor cells and stroma). The 200 percentage of stromal TILs (sTILs) was calculated in accordance with the recommendations by an International TILs Working Group 2014 (Salgado et al., 201 202 2015).

203

204 Programmed cell death-ligand 1 (PD-L1) expression

The expression of programmed cell death-ligand 1 (PD-L1) was characterized by immunohistochemistry (IHC) using anti-PD-L1 (clone SP142, Spring Bioscience, USA) and the percentages of PD-L1 positive tumor cells (TC) or infiltrating inflammatory cells (IC) were quantified.

209

210 Statistical analysis

- 211 All statistical analyses were conducted using SAS 9.4 (North Carolina, USA).
- 212 Continuous data are presented as mean and standard deviation (SD) or mean and 95%
- 213 confidence interval (CI). Categorical data are expressed as frequency and percentage.
- 214 The 95% CIs of pathological complete response rate, proportion of patients with
- 215 RCB-0 or RCB-I, and ORR were estimated using the Clopper-Pearson method.
- 216

```
217 Results
```

218 Patient characteristics

Between November 2021 and January 2022, 12 HR-positive, HER2-negative patients
were screened and recruited in the trial. Their baseline demographic and clinical

- characteristics are shown in **Table 1**. They had a median age of 48.5 years (range, 36-
- 56) and the median tumor size of 33.5mm (range, 23-90) assessed by breast MRI.

223

224 Patient outcomes

225 After the completion of study treatment, 2 (16.7%, 95% CI 3.5%-46.0%) out of 12

patients achieved RCB 0–I tumor response, tpCR and PEPI 0 (Table 2). There were 3

227 (25.0%) patients reached bpCR. Overall, this study led to an ORR (as assessed by

- 228 breast MRI) of 91.7% (95% CI 62.5%-100%, Fig. 1). Rate of conversion from
- 229 mastectomy at baseline to breast conservation at surgery was 25.0% (95% CI 8.3%-

230 53.9%). The median Ki67 of surgical specimens for patients without pCR was 7%231 (range, 5-70).

232

233	To	xic	ity
-----	----	-----	-----

All patients completed the study treatment and AEs are summarized in **Table 3**. The most frequent grade 1-2 AEs were leukopenia (58.3%), hot flushes (50.0%) and lymphopenia (50.0%). There were some patients with Grade 3 AEs, including neutropenia (66.7%) and leukopenia (25.0%), but not grade 4 AEs. There was no serious AEs, no therapy-related death and no patients with dose interruption and reduction or treatment discontinuation in this population. Furthermore, there was no patient with radiation-related dermatitis and skin hyperpigmentation in this population.

241

242 Patient-reported outcome

All patients completed the EORTC QLQ-C30 and had available results of PRO

assessment (Fig. 2). There was no clinically significant deterioration in global health

status, physical, role, emotional, cognitive and social functioning in this population.

246

247 Alteration in tumor immune microenvironment

To examine the impact of this new neoadjuvant therapy on tumor environment, we performed H&E staining of tissue sections in 10 evaluable patients (**Fig. 3**). Compared with those in pre-treatment biopsied tissues, treatment significantly

251	increased the percentages of tumor-infiltrating lymphocytes (TILs) in the tumor
252	environment (22.9% vs.10.7%, P=0.043). IHC staining of PD-L1 revealed that there
253	appeared no significant difference in the percent of PD-L1 positive immune cells and
254	tumor cells between the pre-treatment and post-treatment specimens.

255

256 Discussion

This pioneering study reported the efficacy and safety of sequential neoadjuvant radiotherapy and combination of dalpiciclib and exemestane in patients with HRpositive, HER2-negative breast cancer. This new therapeutic regimen achieved considerable anti-tumor activity with the RCB 0-I rate of 16.7% and ORR rate of 91.7%, respectively. More importantly, this combinatory therapeutic strategy was well tolerated in this population

CDK4/6 inhibitors have recently been preclinically identified as radiosensitizers, 263 acting mainly through hindering DNA damage repair response after radiation 264 exposure, and enhancing cell apoptosis and blocking cell cycle, which provide a 265 conceptual basis of combining radiotherapy with a CDK4/6 inhibitor (Khasraw et al., 266 2017; Xie et al., 2019). Moreover, both radiotherapy and CDK4/6 inhibitors exert 267 immunomodulatory effects and may synergize anticancer immune responses(Andrea 268 M Pesch et al., 2020). SBRT with hypofractionation and higher radiation doses is 269 270 effective than conventional fractionation triggering more in immune responses(Gandhi et al., 2015). Consistent with the basic research(Giulia Petroni et 271

al., 2021), we used the sequential treatment with SBRT and combination ofdalpiciclib and exemestane.

274	Unlike HER2-positive and triple-negative breast cancer, NCT or NET for HR-positive,
275	HER2-negative breast cancer only achieves a pCR rate of \leq 10%(Cortazar et al.,
276	2014) . Our study indicated that this novel therapeutic regiment achieved a pCR and
277	RCB 0-I rate of 16.7% , while neoadjuvant therapies with combination of a CDK4/6
278	inhibitor and letrozole led to a pCR rate of 0-3.8% and RCB 0-I rate of 6.1-7.7% and
279	treatment with NCT resulted in a pCR rate of 5.8-5.9% and RCB 0-I rate of 11.8-15.7%
280	in HR-positive, HER2-negative breast cancer patients(C. X. Ma et al., 2017; Prat et al.,
281	2020). It is notable that pCR rate (commonly defined as ypT0/isN0) is not
282	significantly associated with the prognosis of HR-positive, HER2-negative breast
283	cancer(Cynthia X Ma et al., 2017). In addition, clinical trials to test different therapies
284	for patients with HR-positive, HER2-negative breast cancer have focused on clinical
285	response rates as important clinical endpoints. (Hurvitz et al., 2020; Johnston et al.,
286	2019; Khan et al., 2020; Khasraw et al., 2017; C. X. Ma et al., 2017) In our study,
287	treatment with the new therapeutic regiment led to eleven (91.7%) patients achieving
288	objective responses by MRI, while previous studies have revealed that NET achieves
289	an objective response rate of approximately 60% in HR-positive, HER2-negative
290	breast cancer patients. (Sella et al., 2021) With the addition of SBRT, a slightly higher
291	rate of patients changed from mastectomy to breast conservation compared with
292	PALLET study (25.0% vs 14.1%). (Johnston et al., 2019) Therefore, our new

neoadjuvant therapeutic regiment appeared to improve the likelihood of pathological
downstaging and achieve a margin-free resection, particularly for those with locally
advanced and high-risk breast cancer.

Considering that treatment with radiotherapy or a CDK4/6 inhibitor can enhance anti-296 297 tumor immunity in vitro, We analyzed the impact of new neoadjuvant therapeutic 298 regiment on alternation in biomarker expression in the numbers of TILs before and after the treatment., Our study showed a modest but statistically significant increase in 299 300 the tumor tissues with the addition of SBRT. Apparently, sequential neoadjuvant 301 therapies with radiotherapy, a CDK 4/6 inhibitor and exemestane turned nonresponsive 'cold' tumors into responsive 'hot' ones. Therefore, our findings may 302 303 provide significant insights into designing effective therapeutic strategies against HR-304 positive, HER2-negative breast cancer.

Patients with HR-positive, HER2-negative breast cancer were well-tolerated to the combinational regimen. During the observation period, those patients only developed grade 1-3 of AEs, including grade 3 neutropenia (66.7%), similar to that of combination of dalpiciclib and fulvestrant in the DAWNA-1 trial (84.2%). (Xu et al., 2021) There was no new AEs following therapies with radiotherapy and dalpiciclib in this population.

We recognized that our study had limitations, including a one-arm preliminary exploratory trial with small sample size⁻ The small sample size limited the comparison of our data with historical data in the literature due to the potential bias. Thus, further

- 314 prospective randomized clinical trials with a larger population for longer treatment
- 315 duration are warranted to validate the findings.
- 316 In conclusion, our study provides novel insights into the neoadjuvant treatment of
- 317 HR+/HER2- breast cancer. The sequential radiotherapy and a CDK4/6 inhibitor plus
- 318 ET is feasible as neoadjuvant therapy for HR-positive, HER2 -negative breast cancers.
- 319 This neoadjuvant regimen was effective and well-tolerated, which could serve as a
- 320 promising alternative regimen in treatment of patients with HR-positive, HER2-
- 321 negative breast cancer. Further validation of these findings is warranted in a large-
- 322 scale study.
- 323
- 324
- 325
- 326
- 327
- 328
- 329
- 330
- 331
- 332
- 333

335	
336	
337	
338	
339	
340	
341	
342	Acknowledgments
343	Jiangsu Hengrui Pharmaceuticals provided the study drug dalpiciclib free of charge
344	for patients enrolled in the study. We thank the patients, their families involved in this
345	study.
346	
347	Conflict of interest
348	Jianfei Wang is the employee of Jiangsu Hengrui Pharmaceuticals Co., Ltd. Caigang
349	Liu is a senior editior of eLife. Yongliang Yang is a reviewing editor of eLife. The
350	other authors declare that no competing interests exist.
351	Funding
352	This research did not receive any specific grant from funding agencies in the public,
353	commercial, or not-for-profit sectors.
354	

355 Author ORCIDs : Caigang Liu https://orcid.org/0000-0003-2083-235X

356

357 Data availability statement

The raw clinical and imaging data are protected due to patient privacy laws. The datasets generated and/or analyzed during the current study are available from the corresponding author Caigang Liu on request for 10 years; de-identified clinical data and experimental data are available on request sharing, which will need the approval of the Institutional Ethical Committees. De-identified data will then be transferred to the inquiring investigator over secure file transfer.

364

365 **References**

366 Bosacki, C., Bouleftour, W., Sotton, S., Vallard, A., Daguenet, E., Ouaz, H., Cojoracu, I.,

- 367 Moslemi, D., Molekzadehmoghani, M., & Magné, N. (2021). CDK 4/6 inhibitors
 368 combined with radiotherapy: A review of literature. *Clin Transl Radiat Oncol, 26*, 79-
- 369 85. <u>https://doi.org/10.1016/j.ctro.2020.11.010</u>
- 370
- Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N.,
 Aguilar Lopez, B., Barrios, C. H., Bergh, J., Biganzoli, L., Boers-Doets, C. B.,
 Cardoso, M. J., Carey, L. A., Cortés, J., Curigliano, G., Diéras, V., El Saghir, N. S.,
 Eniu, A., . . Winer, E. P. (2018). 4th ESO-ESMO International Consensus Guidelines
 for Advanced Breast Cancer (ABC 4)†. *Ann Oncol, 29*(8), 1634-1657.

376

https://doi.org/10.1093/annonc/mdy192

- 378 Chmura, S., Winter, K. A., Robinson, C., Pisansky, T. M., Borges, V., Al-Hallaq, H., Matuszak,
- 379 M., Park, S. S., Yi, S., Hasan, Y., Bazan, J., Wong, P., Yoon, H. A., Horton, J., Gan,
- 380 G., Milano, M. T., Sigurdson, E. R., Moughan, J., Salama, J. K., & White, J. (2021).
- 381 Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients
- 382 With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial. JAMA Oncol,
- 383 7(6), 845-852. https://doi.org/10.1001/jamaoncol.2021.0687
- 384
- Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H.,
 Cameron, D., Gianni, L., Valagussa, P., Swain, S. M., Prowell, T., Loibl, S.,
 Wickerham, D. L., Bogaerts, J., Baselga, J., Perou, C., Blumenthal, G., Blohmer,
 J., . . . von Minckwitz, G. (2014). Pathological complete response and long-term
 clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet*, *384*(9938),
 164-172. https://doi.org/10.1016/s0140-6736(13)62422-8
- 391
- Cox, J. A., & Swanson, T. A. (2013). Current modalities of accelerated partial breast
 irradiation. *Nat Rev Clin Oncol*, *10*(6), 344-356.
 <u>https://doi.org/10.1038/nrclinonc.2013.65</u>
- 395

396 Cull, A. (1998). EORTC QLQ-30. A breach of copyright. Int J Pancreatol, 24(1), 64-65.

397 https://doi.org/10.1007/bf02787535

399	Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R.,
400	Pinter, T., Schmidt, M., Shparyk, Y., Thummala, A. R., Voytko, N. L., Fowst, C.,
401	Huang, X., Kim, S. T., Randolph, S., & Slamon, D. J. (2015). The cyclin-dependent
402	kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as
403	first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast
404	cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol, 16(1), 25-
405	35. <u>https://doi.org/10.1016/s1470-2045(14)71159-3</u>
406	
407	Gandhi, S. J., Minn, A. J., Vonderheide, R. H., Wherry, E. J., Hahn, S. M., & Maity, A. (2015).
408	Awakening the immune system with radiation: optimal dose and fractionation. Cancer
409	<i>letters</i> , <i>368</i> (2), 185-190. <u>https://doi: 10.1016/j.canlet.2015.03.024.</u>
410	
411	Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H.,
412	Trédan, O., Chen, S. C., Manso, L., Freedman, O. C., Garnica Jaliffe, G., Forrester,
413	T., Frenzel, M., Barriga, S., Smith, I. C., Bourayou, N., & Di Leo, A. (2017).
414	MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin
415	Oncol, 35(32), 3638-3646. https://doi.org/10.1200/jco.2017.75.6155

417	Gradishar, W. J., Moran, M. S., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Anderson, B.,
418	Burstein, H. J., Chew, H., Dang, C., Elias, A. D., Giordano, S. H., Goetz, M. P.,
419	Goldstein, L. J., Hurvitz, S. A., Isakoff, S. J., Jankowitz, R. C., Javid, S. H.,
420	Krishnamurthy, J., Kumar, R. (2022). Breast Cancer, Version 3.2022, NCCN
421	Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 20(6), 691-722.
422	https://doi.org/10.6004/jnccn.2022.0030
423	
424	Han, Y. K., Lee, J. H., Park, G. Y., Chun, S. H., Han, J. Y., Kim, S. D., Lee, J., Lee, C. W.,
425	Yang, K., & Lee, C. G. (2013). A possible usage of a CDK4 inhibitor for breast cancer
426	stem cell-targeted therapy. Biochem Biophys Res Commun, 430(4), 1329-1333.
427	https://doi.org/10.1016/j.bbrc.2012.10.119
428	
429	Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S.,
430	Campone, M., Blackwell, K. L., André, F., Winer, E. P., Janni, W., Verma, S., Conte,
431	P., Arteaga, C. L., Cameron, D. A., Petrakova, K., Hart, L. L., Villanueva, C., Chan,
432	A., O'Shaughnessy, J. (2016). Ribociclib as First-Line Therapy for HR-Positive,
433	Advanced Breast Cancer. N Engl J Med, 375(18), 1738-1748.
434	https://doi.org/10.1056/NEJMoa1609709
435	

436	Hurvitz, S. A., Martin, M., Press, M. F., Chan, D., Fernandez-Abad, M., Petru, E., Rostorfer,
437	R., Guarneri, V., Huang, C. S., Barriga, S., Wijayawardana, S., Brahmachary, M.,
438	Ebert, P. J., Hossain, A., Liu, J., Abel, A., Aggarwal, A., Jansen, V. M., & Slamon, D.
439	J. (2020). Potent Cell-Cycle Inhibition and Upregulation of Immune Response with
440	Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in
441	HR(+)/HER2(-) Breast Cancer. <i>Clin Cancer Res</i> , <i>26</i> (3), 566-580.
442	https://doi.org/10.1158/1078-0432.CCR-19-1425
443	

444 Johnston, S., Puhalla, S., Wheatley, D., Ring, A., Barry, P., Holcombe, C., Boileau, J. F., 445 Provencher, L., Robidoux, A., Rimawi, M., McIntosh, S. A., Shalaby, I., Stein, R. C., 446 Thirlwell, M., Dolling, D., Morden, J., Snowdon, C., Perry, S., Cornman, C., . . . 447 Jacobs, S. A. (2019). Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast 448 449 Cancer: PALLET Trial. *37*(3), 178-189. J Clin Oncol, 450 https://doi.org/10.1200/jco.18.01624

451

Khan, Q. J., O'Dea, A., Bardia, A., Kalinsky, K., Wisinski, K. B., O'Regan, R., Yuan, Y., Ma, C.
X., Jahanzeb, M., Trivedi, M. S., Spring, L., Makhoul, I., Wagner, J. L., Winblad, O.,
Amin, A. L., Blau, S., Crane, G. J., Elia, M., Hard, M., & Sharma, P. (2020). Letrozole
+ ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer

456	(FELINE trial). <i>Journal of Clinical Oncology</i> , <i>38</i> (15_suppl), 505-505.
457	https://doi.org/10.1200/JCO.2020.38.15_suppl.505
458	
459	Khasraw, M., Chung, S., Day, B., Johns, T., Joshi, S., Madani, D., McDonald, K., & Whittaker,
460	S. (2017). Combination of palbociclib and radiotherapy for glioblastoma. Cell Death
461	Discov 2017;3:17033. https://doi: 10.1038/cddiscovery.2017.33.
462	
463	Ma, C. X., Gao, F., Luo, J., Northfelt, D. W., Goetz, M., Forero, A., Hoog, J., Naughton, M.,
464	Ademuyiwa, F., Suresh, R., Anderson, K. S., Margenthaler, J., Aft, R., Hobday, T.,
465	Moynihan, T., Gillanders, W., Cyr, A., Eberlein, T. J., Hieken, T., Ellis, M. J.
466	(2017). NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor,
467	and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.
468	<i>Clin Cancer Res</i> , <i>23</i> (15), 4055-4065. <u>https://doi.org/10.1158/1078-0432.Ccr-16-3206</u>
469	
470	Parker, J. S., Mullins, M., Cheang, M. C., Leung, S., Voduc, D., Vickery, T., Davies, S.,
471	Fauron, C., He, X., Hu, Z., Quackenbush, J. F., Stijleman, I. J., Palazzo, J., Marron, J.
472	S., Nobel, A. B., Mardis, E., Nielsen, T. O., Ellis, M. J., Perou, C. M., & Bernard, P. S.
473	(2009). Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin
474	Oncol, 27(8), 1160-1167. https://doi.org/10.1200/jco.2008.18.1370
475	

476	Pesch, A. M., Hirsh, N. H., Chandler, B. C., Michmerhuizen, A. R., Ritter, C. L., Androsiglio, M.
477	P., Wilder-Romans, K., Liu, M., Gersch, C. L., Larios, J. M., Pierce, L. J., Rae, J. M.,
478	& Speers, C. W. (2020). Short-term CDK4/6 Inhibition Radiosensitizes Estrogen
479	Receptor-Positive Breast Cancers. <i>Clin Cancer Res</i> , <i>26</i> (24), 6568-6580.
480	https://doi.org/10.1158/1078-0432.Ccr-20-2269
481	
482	Petroni, G., Buqué, A., Yamazaki, T., Bloy, N., Liberto, M. D., Chen-Kiang, S., Formenti, S. C.,
483	& Galluzzi, L. (2021). Radiotherapy Delivered before CDK4/6 Inhibitors Mediates
484	Superior Therapeutic Effects in ER(+) Breast Cancer. Clin Cancer Res, 27(7), 1855-
485	1863. https://doi.org/10.1158/1078-0432.Ccr-20-3871
486	
487	Prat, A., Saura, C., Pascual, T., Hernando, C., Muñoz, M., Paré, L., Farré, B. G., Fernández,
488	P. L., Galván, P., & Chic, N. (2020). Ribociclib plus letrozole versus chemotherapy for
489	postmenopausal women with hormone receptor-positive, HER2-negative, luminal B
490	breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
491	The lancet oncology, 21(1), 33-43. https://doi: 10.1016/s1470-2045(19)30786-7.
492	
493	Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S.,
494	Van den Eynden, G., Baehner, F. L., Penault-Llorca, F., Perez, E. A., Thompson, E.
495	A., Symmans, W. F., Richardson, A. L., Brock, J., Criscitiello, C., Bailey, H., Ignatiadis,

496	M., Floris, G., Loi, S. (2015). The evaluation of tumor-infiltrating lymphocytes
497	(TILs) in breast cancer: recommendations by an International TILs Working Group
498	2014. Ann Oncol, 26(2), 259-271. https://doi.org/10.1093/annonc/mdu450
499	
500	Sella, T., Weiss, A., Mittendorf, E. A., King, T. A., Pilewskie, M., Giuliano, A. E., & Metzger-
501	Filho, O. (2021). Neoadjuvant Endocrine Therapy in Clinical Practice: A Review.
502	JAMA Oncol, 7(11), 1700-1708. <u>https://doi.org/10.1001/jamaoncol.2021.2132</u>
503	
504	Xie, X., Zheng, W., Chen, T., Lin, W., Liao, Z., Liu, J., & Ding, Y. (2019). CDK4/6 inhibitor
505	palbociclib amplifies the radiosensitivity to nasopharyngeal carcinoma cells via
506	mediating apoptosis and suppressing DNA damage repair. OncoTargets and therapy,
507	11107-11117. <u>https://doi: 10.2147/ott.S234221.</u>
508	
509	Xu, B., Zhang, Q., Zhang, P., Hu, X., Li, W., Tong, Z., Sun, T., Teng, Y., Wu, X., Ouyang, Q.,
510	Yan, X., Cheng, J., Liu, Q., Feng, J., Wang, X., Yin, Y., Shi, Y., Pan, Y., Wang, Y.,
511	Zou, J. (2021). Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive
512	and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat Med,
513	<i>27</i> (11), 1904-1909. <u>https://doi.org/10.1038/s41591-021-01562-9</u>
514	
515	

516 Table 1: Baseline characteristics of the patients.

	Patients (n=12)	
Median age (range), years	48.5 (36-56)	
≤ 50	6 (50.0%)	
> 50	6 (50.0%)	
Menopausal status		
Premenopausal	6 (50.0%)	
Postmenopausal	6 (50.0%)	
Tumor size		
T2	11 (91.7%)	
Т3	1 (8.3%)	
Lymph node status		
N0	5 (41.7%)	
N1	2 (16.7%)	
N2	5 (41.7%)	
Clinical stage		
IIA	4 (33.3%)	
IIB	3 (25.0%)	
IIIA	5 (41.7%)	
Tumor grade		
II	11 (91.7%)	
III	1 (8.3%)	
ER expression		
> 10%	12 (100.0%)	
PgR expression		
< 20%	3 (25.0%)	
≥ 20%	9 (75.0%)	
HER2 expression		
Negative	7 (58.3%)	
1+	1 (8.3%)	
2+, FISH	4 (33.3%)	
Median baseline Ki67 (range), %	35 (15-70)	
≤ 14%	3 (25.0%)	
> 14%	9 (75.0%)	

Data are n (%) or median (range).

ER: estrogen receptor; PgR: progesterone receptor; HER2: human epidermal growth

factor receptor 2; FISH: fluorescence in situ hybridization.

Table 2: Pathological and clinical response (n=12). 517

	n (%)
Total pathological complete response	2 (16.7%)
Breast pathological complete response	3 (25.0%)
Residual cancer burden score	
0	2 (16.7%)
I	0
II	6 (50.0%)
III	4 (33.3%)
Radiological response	
Complete response	2 (16.7%)
Partial response	9 (75.0%)
Stable disease	1 (8.3%)
Objective response rate	11 (91.7%)
Preoperative endocrine prognostic	
index	
0	2 (16.7%)
1-3	0
≥4	10 (83.3%)

Data are presented as n (%)

518

519

		n (%)	
	Grade 1 or 2	Grade 3	Grade 4
Neutropenia	3 (25.0%)	8 (66.7%)	0
Leukopenia	7 (58.3%)	3 (25.0%)	0
Hot flushes	6 (50.0%)	0	0
Lymphopenia	6 (50.0%)	0	0
Insomnia	4 (33.3%)	0	0
Alopecia	4 (33.3%)	0	0
Anemia	4 (33.3%)	0	0
Hyperuricemia	4 (33.3%)	0	0
Blood urea increased	4 (33.3%)	0	0
Rash	3 (25.0%)	0	0
Thrombocytopenia	3 (25.0%)	0	0
Hyperglycemia	3 (25.0%)	0	0
Creatinine increased	3 (25.0%)	0	0
Fatigue	3 (25.0%)	0	0
Arthralgia	2 (16.7%)	0	0
γ-glutamyl transferase increased	2 (16.7%)	0	0
Hypocalcemia	2 (16.7%)	0	0
Abnormal T wave of	2(1(.70/))	0	0
electrocardiogram	2 (16.7%)	0	0
Hyponatremia	2 (16.7%)	0	0
Lactate dehydrogenase increased	2 (16.7%)	0	0
Diarrhea	1 (8.3%)	0	0
Headache	1 (8.3%)	0	0
Mucosal inflammation Constipation	1 (8.3%)	0	0
Proteinuria	1 (8.3%)	0	0
Hypertriglyceridemia	1 (8.3%)	0	0
Alanine aminotransferase increased	1 (8.3%)	0	0


Table 3: Treatment-emergent adverse events (n=12). 521

Data are presented as n (%).

524 Figure legends

525

- 526 Figure 1: Waterfall plot of best reduction in tumor measurement from basline.
- 527 Figure 2: Mean change from baseline in QLQ-C30 over time. (A) Global health
- 528 status. (B-F) Physical, role, emotional, cognitive and social functioning.
- **Figure 3:** TILs and PD-L1 changes before and after treatment. (A) Study schema. (B)
- 530 Representative TILs. Scale bar, 100 μM. (C-E) Percentage of TILs, PD-L1 expression
- in immune cell and tumor cell in paired specimens (n=10). Bars, boxes, and whiskers
- 532 represent median, interquartile range, and range, respectively.



SBRT-Dalpiciclib+Exemestane

